Skip to main content
. 2020 Aug 24;15:205. doi: 10.1186/s13014-020-01646-9

Fig. 3.

Fig. 3

Pooled PFS rates for ECRT group, 1-year (a), 2-year (b), and 3-year PFS rates (c). PFS: progression-free survival; ECRT: endostatin combined with concurrent chemoradiotherapy